MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Curium

News headline image
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
From Curium
Via GlobeNewswire
News headline image
CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally
From Curium
Via GlobeNewswire
News headline image
Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts
From Curium
Via GlobeNewswire
News headline image
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
From Curium
Via GlobeNewswire
News headline image
Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals
From Curium
Via GlobeNewswire
News headline image
Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
From Curium
Via GlobeNewswire
News headline image
Curium Announces Approval of Generic DTPA - Kit for the Preparation of Technetium Tc 99m Pentetate Injection in the U.S.
From Curium
Via GlobeNewswire
News headline image
Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint
From Curium
Via GlobeNewswire
News headline image
Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
From Curium
Via GlobeNewswire
News headline image
Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
From Curium
Via GlobeNewswire
News headline image
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
From Curium
Via GlobeNewswire
News headline image
Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
From Curium
Via GlobeNewswire
News headline image
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
From Curium
Via GlobeNewswire
News headline image
Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years
From Curium
Via GlobeNewswire
News headline image
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
From Curium
Via GlobeNewswire
News headline image
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
From Curium
Via GlobeNewswire
News headline image
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
From Curium
Via GlobeNewswire
News headline image
Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol
From Curium
Via GlobeNewswire
News headline image
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
From Curium
Via GlobeNewswire
News headline image
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
From Curium
Via GlobeNewswire
News headline image
Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
From Curium
Via GlobeNewswire
News headline image
Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany to Enable Tomographic 3D Ultrasound Solutions
From Curium
Via GlobeNewswire
News headline image
Curium Announces Achievement of Co-Primary Endpoints in Phase 2 of Its Phase 1/2 SOLAR Clinical Trial Imaging Men With Histologically-Proven Prostate Cancer Using Copper Cu 64 PSMA I&T
From Curium
Via GlobeNewswire
News headline image
Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer
From Curium
Via GlobeNewswire
News headline image
Curium Announces License and Development Agreement With Lantheus for AI-Based PSMA PET Software in Europe
From Curium
Via GlobeNewswire
News headline image
Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)
From Curium
Via GlobeNewswire
News headline image
Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific
From Curium
Via GlobeNewswire
News headline image
Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial Imaging Men with Histologically-Proven Metastatic Prostate Cancer Using Copper Cu 64 PSMA I&T.
From Curium
Via GlobeNewswire
News headline image
Curium Confirms No Supply Challenges in North America and Europe for its Eclipse Phase 3 Clinical Trial
From Curium
Via GlobeNewswire
News headline image
Curium’s 14 Million Patients to Benefit From Regular Supply of Mo-99 and Tc-99
From Curium
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story